Transocean (NYSE: RIG), WellPoint, Inc. (NYSE: WLP), Warren Resources, Inc. (NASDAQ: WRES), Humana (NYSE: HUM) and Motorola Mobility (NYSE: MMI) had their price targets changed by analysts.
Credit Suisse (NYSE:CS) slashed its price target on Transocean (RIG) to $72.00. They have a "Neutral" rating on the company.
Wedbush boosted its price target on WellPoint, Inc. (WLP) to $83.00.
Pritchard cut its price target on Warren Resources, Inc. (WRES) to $5.50.
Wedbush raised its price target on Humana (NYSE: HUM) to $90.00.
RBC Capital lowered its price target on Motorola Mobility (MMI) from $33.00 to $27.00. They have a “Sector Perform” rating on the company.
Showing posts with label Wellpoint. Show all posts
Showing posts with label Wellpoint. Show all posts
Friday, July 15, 2011
Monday, May 2, 2011
Dividend Yields for (AET) (COV) (PDCO) (HUM) (WLP)
Indicated dividend yields for Standard & Poor's 500 Index companies Aetna Inc (AET), Covidien PLC (COV), Patterson Cos Inc (PDCO), Humana Inc (HUM) and WellPoint Inc (WLP).
These dividend data indicate dividend yields of companies in the Standard & Poor's 500 Index as of Saturday, April 30. The yield is determined by taking the latest declared dividend, annualized and divided by the price of the stock. Payout ratios are calculated based on latest quarterly dividend paid divided by earnings.
Aetna Inc (AET) has a dividend yield of 1.45 percent on a declared dividend of $0.15. The payout ratio is 9.8 percent.
Covidien PLC (COV) has a dividend yield of 1.44 percent on a declared dividend of $0.20. The payout ratio is 22.9 percent.
Patterson Cos Inc (PDCO) has a dividend yield of 1.38 percent on a declared dividend of $0.12. The payout ratio is 21.3 percent.
Humana Inc (HUM) has a dividend yield of 1.31 percent on a declared dividend of $0.25. The payout ratio is na.
WellPoint Inc (WLP) has a dividend yield of 1.30 percent on a declared dividend of $0.25. The payout ratio is 10.1 percent.
These dividend data indicate dividend yields of companies in the Standard & Poor's 500 Index as of Saturday, April 30. The yield is determined by taking the latest declared dividend, annualized and divided by the price of the stock. Payout ratios are calculated based on latest quarterly dividend paid divided by earnings.
Aetna Inc (AET) has a dividend yield of 1.45 percent on a declared dividend of $0.15. The payout ratio is 9.8 percent.
Covidien PLC (COV) has a dividend yield of 1.44 percent on a declared dividend of $0.20. The payout ratio is 22.9 percent.
Patterson Cos Inc (PDCO) has a dividend yield of 1.38 percent on a declared dividend of $0.12. The payout ratio is 21.3 percent.
Humana Inc (HUM) has a dividend yield of 1.31 percent on a declared dividend of $0.25. The payout ratio is na.
WellPoint Inc (WLP) has a dividend yield of 1.30 percent on a declared dividend of $0.25. The payout ratio is 10.1 percent.
Thursday, April 28, 2011
Ratings on (SYA) (TER) (WDR) (WLP) Reiterated
Ratings on Symetra Financial (NYSE: SYA), Teradyne, Inc. (NYSE: TER), Waddell & Reed Financial, Inc. (NYSE: WDR) and WellPoint, Inc. (NYSE: WLP) reiterated by analysts.
JPMorgan Chase & Co. (NYSE:JPM) reiterated a “neutral” rating on Symetra Financial (SYA). They have a price target of $15 on the company.
Citigroup (NYSE:C) reiterated a “buy” rating on Teradyne, Inc. (TER). They have a price target of $24.00 on the company.
Citigroup reiterated a “buy” rating on Waddell & Reed Financial, Inc. (WDR). They now have a price target of $48 on the company.
Morgan Stanley (NYSE:MS) reiterated an “overweight” rating on WellPoint, Inc. (WLP). They now have a price target of $90 on the company.
JPMorgan Chase & Co. (NYSE:JPM) reiterated a “neutral” rating on Symetra Financial (SYA). They have a price target of $15 on the company.
Citigroup (NYSE:C) reiterated a “buy” rating on Teradyne, Inc. (TER). They have a price target of $24.00 on the company.
Citigroup reiterated a “buy” rating on Waddell & Reed Financial, Inc. (WDR). They now have a price target of $48 on the company.
Morgan Stanley (NYSE:MS) reiterated an “overweight” rating on WellPoint, Inc. (WLP). They now have a price target of $90 on the company.
WellPoint (WLP) (TMO) (WU) (WYN) Get Ratings Reiterated by Analysts
WellPoint, Inc. (NYSE: WLP), Thermo Fisher Scient (NYSE: TMO), The Western Union Company (NYSE: WU) and Wyndham Worldwide (NYSE: WYN) get ratings reiterated by analysts.
Morgan Stanley reiterated an “Overweight” rating on Thermo Fisher Scient (TMO).
Deutsche Bank (NYSE:DB) reiterated a “Buy” rating on WellPoint, Inc. (WLP).
Morgan Stanley (NYSE:MS) reiterated an “Overweight” rating on The Western Union Company (WU).
Piper Jaffray reiterated an “Overweight” rating on The Western Union Company (WU). They have a price target of $26 on the firm.
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “Overweight” rating on shares of Wyndham Worldwide (WYN).
Morgan Stanley reiterated an “Overweight” rating on Thermo Fisher Scient (TMO).
Deutsche Bank (NYSE:DB) reiterated a “Buy” rating on WellPoint, Inc. (WLP).
Morgan Stanley (NYSE:MS) reiterated an “Overweight” rating on The Western Union Company (WU).
Piper Jaffray reiterated an “Overweight” rating on The Western Union Company (WU). They have a price target of $26 on the firm.
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “Overweight” rating on shares of Wyndham Worldwide (WYN).
Friday, January 28, 2011
WellPoint (NYSE:WLP) Still Trails Peers on Upside
WellPoint (NYSE:WLP) continues to struggle to match up with their peers on the upside, noted UBS, who sees them still improving earnings in 2011, and raised the EPS estimate on them accordingly.
UBS says, "While Q4 was ahead of our expectation ex-items (impairments/tax rate/reserve release) upside continues to trail peers on efficiency/IT investments and CA individual headwind. For 2011, flat EBIT no longer a “stretch goal” and appears extremely achievable as CA improvement + easy SG&A comp should offset much of $300m MLR floor impact. Raise EPS to $6.60 to reflect flat-EBIT assumption coupled w/more optimistic below-line outlook despite mgmt conservatism.
"We est. WLP EPS guidance implies average 2011 share-count that is only 1% below est. YE 2010 levels. Assuming $2B buyback (only 50% of $4B deployable cash) ratably over 2011 we get -$0.19 of upside to guidance of 'at least $6.30.' Investment income decline of 15% or $125m YoY and interest expense of $500m (despite $450m run-rate and $700m of pay-down in Jan.) likely leaves additional $0.15 of cushion, implying more realistic 2011 earnings power of $6.50-$6.75."
UBS maintains a "Buy" rating on WellPoint (WLP), which closed Thursday at $64.36, gaining $1.81, or 2.89 percent. UBS raised their price target on WellPoint from $71 to $73.
UBS says, "While Q4 was ahead of our expectation ex-items (impairments/tax rate/reserve release) upside continues to trail peers on efficiency/IT investments and CA individual headwind. For 2011, flat EBIT no longer a “stretch goal” and appears extremely achievable as CA improvement + easy SG&A comp should offset much of $300m MLR floor impact. Raise EPS to $6.60 to reflect flat-EBIT assumption coupled w/more optimistic below-line outlook despite mgmt conservatism.
"We est. WLP EPS guidance implies average 2011 share-count that is only 1% below est. YE 2010 levels. Assuming $2B buyback (only 50% of $4B deployable cash) ratably over 2011 we get -$0.19 of upside to guidance of 'at least $6.30.' Investment income decline of 15% or $125m YoY and interest expense of $500m (despite $450m run-rate and $700m of pay-down in Jan.) likely leaves additional $0.15 of cushion, implying more realistic 2011 earnings power of $6.50-$6.75."
UBS maintains a "Buy" rating on WellPoint (WLP), which closed Thursday at $64.36, gaining $1.81, or 2.89 percent. UBS raised their price target on WellPoint from $71 to $73.
Thursday, January 27, 2011
WellPoint (NYSE:WLP) Still Trails Peers on Upside
WellPoint (NYSE:WLP) continues to struggle to match up with their peers on the upside, noted UBS, who sees them still improving earnings in 2011, and raised the EPS estimate on them accordingly.
UBS says, "While Q4 was ahead of our expectation ex-items (impairments/tax rate/reserve release) upside continues to trail peers on efficiency/IT investments and CA individual headwind. For 2011, flat EBIT no longer a “stretch goal” and appears extremely achievable as CA improvement + easy SG&A comp should offset much of $300m MLR floor impact. Raise EPS to $6.60 to reflect flat-EBIT assumption coupled w/more optimistic below-line outlook despite mgmt conservatism.
"We est. WLP EPS guidance implies average 2011 share-count that is only 1% below est. YE 2010 levels. Assuming $2B buyback (only 50% of $4B deployable cash) ratably over 2011 we get -$0.19 of upside to guidance of 'at least $6.30.' Investment income decline of 15% or $125m YoY and interest expense of $500m (despite $450m run-rate and $700m of pay-down in Jan.) likely leaves additional $0.15 of cushion, implying more realistic 2011 earnings power of $6.50-$6.75."
UBS maintains a "Buy" rating on WellPoint (WLP), which closed Thursday at $64.36, gaining $1.81, or 2.89 percent. UBS raised their price target on WellPoint from $71 to $73.
UBS says, "While Q4 was ahead of our expectation ex-items (impairments/tax rate/reserve release) upside continues to trail peers on efficiency/IT investments and CA individual headwind. For 2011, flat EBIT no longer a “stretch goal” and appears extremely achievable as CA improvement + easy SG&A comp should offset much of $300m MLR floor impact. Raise EPS to $6.60 to reflect flat-EBIT assumption coupled w/more optimistic below-line outlook despite mgmt conservatism.
"We est. WLP EPS guidance implies average 2011 share-count that is only 1% below est. YE 2010 levels. Assuming $2B buyback (only 50% of $4B deployable cash) ratably over 2011 we get -$0.19 of upside to guidance of 'at least $6.30.' Investment income decline of 15% or $125m YoY and interest expense of $500m (despite $450m run-rate and $700m of pay-down in Jan.) likely leaves additional $0.15 of cushion, implying more realistic 2011 earnings power of $6.50-$6.75."
UBS maintains a "Buy" rating on WellPoint (WLP), which closed Thursday at $64.36, gaining $1.81, or 2.89 percent. UBS raised their price target on WellPoint from $71 to $73.
Tuesday, January 25, 2011
WellPoint's (NYSE:WLP) 2011 Guidance Expected to be Strong
The upcoming 2010 earnings report from WellPoint (NYSE:WLP) is expected to be solid, with guidance for 2011 even better, according to Jefferies (NYSE:JEF).
This should give a nice boost in share price for WellPoint, which has fallen behind other diversified HMOs by 100-400 bps in January. Still, they've had a decent January, rising by over 8 percent so far.
Another positive outlook is the cash the company has on hand suggest the probability of a repurchase of shares in the 10 to 15 percent range.
Jefferies is maintaining their "Buy" rating on WellPoint (WLP), which closed Monday at $60.99, falling $0.46, or 0.75 percent. They boosted their price target on WellPoint from $69 to $72.
This should give a nice boost in share price for WellPoint, which has fallen behind other diversified HMOs by 100-400 bps in January. Still, they've had a decent January, rising by over 8 percent so far.
Another positive outlook is the cash the company has on hand suggest the probability of a repurchase of shares in the 10 to 15 percent range.
Jefferies is maintaining their "Buy" rating on WellPoint (WLP), which closed Monday at $60.99, falling $0.46, or 0.75 percent. They boosted their price target on WellPoint from $69 to $72.
Wednesday, December 22, 2010
WellPoint (NYSE:WLP) Assets Position Them for Long-term Success
The quality of assets under the control of WellPoint (NYSE:WLP) has them positioned for success over the long term, according to Barclays (NYSE:BCS).
Barclays said, "We believe that WellPoint controls a preferred set of assets for long-term success in health insurance. The company has a broad set of products allowing for participation in various areas of growth. As a Blues licensee, the company maintains one of the only strong brand advantages in a business that is moving closer to the consumer. Additionally, WellPoint maintains leading local market share, which we see as the ultimate characteristic of success for this industry. After a period of industry and company dislocation, our thesis is simply that it is time for WellPoint to execute on its basic strategy. We believe success on this path should provide strong returns for investors."
Barclays maintains an "Overweight" on WellPoint, which closed Tuesday at $56.56, up $0.46, or 0.82 percent. Barclays has a price target on them of $74.
Barclays said, "We believe that WellPoint controls a preferred set of assets for long-term success in health insurance. The company has a broad set of products allowing for participation in various areas of growth. As a Blues licensee, the company maintains one of the only strong brand advantages in a business that is moving closer to the consumer. Additionally, WellPoint maintains leading local market share, which we see as the ultimate characteristic of success for this industry. After a period of industry and company dislocation, our thesis is simply that it is time for WellPoint to execute on its basic strategy. We believe success on this path should provide strong returns for investors."
Barclays maintains an "Overweight" on WellPoint, which closed Tuesday at $56.56, up $0.46, or 0.82 percent. Barclays has a price target on them of $74.
Subscribe to:
Posts (Atom)